Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…licated by cytomegalovirus infection, successfully treated with valganciclovir. A repeat colonoscopy demonstrated complete mucosal healing and…
… and extracellular matrix (ECM) dysfunction, is associated with ustekinumab and anti-TNF resistance (Pavlidis et al. 2022). Its receptor is…
…e from LTE wk 0 through wk 96 for inflammatory markers, hs-CRP (UPA15: -12.4, -12.0; UPA30: -12.7, -10.1) and FCP (UPA15: -2752, -326…
…ngs provide mechanistic support for early or combination use of upadacitinib alongside corticosteroids in ASUC and strengthen the rationale …
…Introduction Upadacitinib (UPA) is an oral, reversible Janus tyrosine kinase inhibitor (J…
…Introduction Upadacitinib (UPA), an oral, reversible Janus kinase inhibitor is approved f…
…ed so was discontinued.Other medications tried were colchicine, hydroxychloroquine, IV-Ig, and cyclosporine, tocilizumab and abatacept with subopt…
…factor inhibitors were ineffective or poorly tolerated, whereas tofacitinib and upadacitinib induced rapid and durable improvement across a…
…h anti-IL23-naïve individuals and those previously treated with Ustekinumab, in real-world clinical practice at a tertiary hospital.Materia…
… two JAKi, and another 7% have received three. Drugs used were: upadacitinib (40%), baricitinib (35%), tofacitinib (24%), and filgotinib (11…
… refractory to multiple therapies, highlighting the response to rituximab. Prior reports support the benefit of rituximab in SLE-associat…